Related Experiment Video
Updated: Aug 1, 2026

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
A new rat model of otitis media caused by Streptococcus pneumoniae: conditions and application in immunization
L T van der Ven1, G P van den Dobbelsteen, B Nagarajah
1Laboratory of Pathology, National Institute of Public Health and the Environment, Bilthoven, The Netherlands. L.van.der.ven@rivm.nl
Abstract:
Streptococcus pneumoniae (pneumococcus [Pn]) can be cultured from up to 50% of acute otitis media (AOM) effusions, and these bacteria are the most common cause of AOM-related complications. With the recent advent of antibiotic-resistant Pn strains, treatment of Pn infections may meet with serious difficulties. Prevention through vaccination, notably for the four most common occurring Pn serotypes in humans (i.e., Pn 6B, Pn 14, Pn 19F, and Pn 23F), is a helpful alternative. Testing of vaccine efficacy should occur in an appropriate animal AOM model, which is presented here. The four involved Pn serotypes are not pathogenic to the rat, which was chosen as the experimental animal for practical reasons. To induce a natural infection (i.e., ascending through the eustachian tube), the mucociliary clearance of the eustachian tube was impaired by infusing histamine into the tympanic cavity on 2 consecutive days before intranasal inoculation of the bacteria. With this simple protocol, high and reproducible infection rates, as determined with bacterial cultures, of Pn-induced AOM (approximately 70%) with the two major Pn serotypes 14 and 19F (Pn 14 and Pn 19F) were obtained, whereas lower infection rates (25 to 50%) with Pn 6B and Pn 23F were obtained. In this model, intranasal priming with pneumococci, as well as subcutaneous vaccination with Pn 14 tetanus toxoid-conjugated polysaccharide, induced a protective effect against the induction of otitis media with these bacteria. This shows that immunity to Pn 14 AOM can be induced by both mucosal and systemic presentations of antigen. In conclusion, we have developed an animal model for Pn-induced AOM, which is suitable for the evaluation of the protecting effect of immunization.
Insights
A new rat model effectively simulates Streptococcus pneumoniae (pneumococcus) induced acute otitis media (AOM), proving useful for testing vaccine efficacy against resistant strains.
Area of Science:
- Microbiology
- Immunology
- Otolaryngology
Background:
- Streptococcus pneumoniae (Pn) is a leading cause of acute otitis media (AOM) and its complications.
- Antibiotic-resistant Pn strains pose significant treatment challenges.
- Vaccination is a key strategy for preventing Pn infections, particularly against common serotypes.
Purpose of the Study:
- To develop and validate an animal model for studying Pn-induced AOM.
- To assess the efficacy of immunization strategies against Pn AOM in this model.
Main Methods:
- Rats were used as the experimental animal due to practical considerations.
- Eustachian tube mucociliary clearance was impaired using histamine infusion.
- Intranasal inoculation with specific Pn serotypes (6B, 14, 19F, 23F) was performed to induce AOM.
- Bacterial cultures were used to determine infection rates.
Main Results:
- A reproducible AOM infection rate of approximately 70% was achieved with Pn serotypes 14 and 19F.
- Lower infection rates (25-50%) were observed with Pn serotypes 6B and 23F.
- Both intranasal priming and subcutaneous vaccination with Pn 14 antigen conferred protection against AOM induction.
Conclusions:
- An effective animal model for Pn-induced AOM has been established.
- This model is suitable for evaluating the protective effects of immunization against AOM.
- Both mucosal and systemic antigen exposure can induce protective immunity against Pn 14 AOM.
More Related Videos
08:25Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
Published on: April 7, 2015
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017